Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: a protocol of a META-epidemiological study

Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: a protocol of a META-epidemiological study

Abstract Background The coronavirus disease 19 (covid-19) pandemic has underscored the need to expedite clinical research, which may lead investigators to shift away from measuring patient-important outcomes (PIO), limiting research applicability. We aim to investigate if randomized controlled trial...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Mario A. Jimenez-Mora, Andrea Ramírez Varela, Jose F. Meneses-Echavez, Julia Bidonde, Adriana Angarita-Fonseca, Reed A. C. Siemieniuk, Dena Zeraatkar, Jessica J. Bartoszko, Romina Brignardello-Petersen, Kimia Honarmand, Bram Rochwerg, Gordon Guyatt, Juan José Yepes-Nuñez
Format: article
Langue:EN
Publié: BMC 2021
Sujets:
Patient-important outcome
Reporting
Treatment
Prevention
Coronavirus
Covid-19
Medicine
R
Accès en ligne:https://doaj.org/article/4ad1c46a4def4d14a7cd3c8366c1070a
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/4ad1c46a4def4d14a7cd3c8366c1070a

Documents similaires